Kyowa Kirin (KYKOF) News Today $17.14 0.00 (0.00%) As of 06/13/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock KYKOF Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Kura Oncology rises after new early-stage trial data for leukemia therapyJune 12 at 5:12 PM | msn.comKyowa Kirin: New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphataemia (XLH)May 29, 2025 | finanznachrichten.de35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRINApril 3, 2025 | prnewswire.comAmgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 StudyMarch 12, 2025 | benzinga.comAmgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpointsMarch 10, 2025 | msn.comAmgen, Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpointsMarch 10, 2025 | finance.yahoo.comAmgen, Kyowa announces new results from ongoing ROCKET Phase 3 studyMarch 10, 2025 | markets.businessinsider.comJefferies Remains a Buy on Kyowa Kirin Co (KYKOF)March 9, 2025 | markets.businessinsider.comJ.P. Morgan Sticks to Its Hold Rating for Kyowa Kirin Co (KYKOF)March 8, 2025 | markets.businessinsider.comKyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025February 26, 2025 | prnewswire.comKura, Kyowa Kirin announce KOMET-001 results, FDA feedback for trial designsFebruary 5, 2025 | markets.businessinsider.comKyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern EuropeJanuary 30, 2025 | businesswire.comAlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery PlatformJanuary 28, 2025 | globenewswire.comKura Oncology: Sentiment Is Too NegativeJanuary 23, 2025 | seekingalpha.comCimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell TherapiesDecember 9, 2024 | businesswire.comAnalysts supportive of Kura/Kirin deal despite major selloff (update)November 21, 2024 | seekingalpha.comKura Oncology Shares Fall 14% on Plans for Cancer-Drug CollaborationNovember 20, 2024 | marketwatch.comKura Oncology, Kyowa Kirin to develop and commercialize ziftomenib in leukemiasNovember 20, 2024 | markets.businessinsider.comKura Oncology Partners With Kyowa Kirin To Develop Ziftomenib For Acute Leukemias; Stock DropsNovember 20, 2024 | markets.businessinsider.comKura Oncology to partner with Kyowa Kirin for blood cancer therapyNovember 20, 2024 | reuters.comKyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical CompanyOctober 31, 2024 | businesswire.comKyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024October 8, 2024 | businesswire.comKyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic DermatitisSeptember 25, 2024 | prnewswire.comKyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual MeetingSeptember 19, 2024 | prnewswire.comA Promising Pipeline Ready to Break out at BridgeBio Pharma (BBIO)September 8, 2024 | msn.comKyowa Kirin Co., Ltd. (KYKOF)August 30, 2024 | sg.finance.yahoo.comKyowa Kirin to end distribution of Fareston (toremefine) in the United StatesAugust 23, 2024 | prnewswire.comKyowa Kirin Co., Ltd. (KYKOY)August 21, 2024 | uk.finance.yahoo.comKyowa Kirin Non-GAAP EPS of ¥70.75, revenue of ¥232.9BAugust 3, 2024 | msn.comJapan Drugmaker Kyowa Kirin Sells China Unit for $100 MillionAugust 1, 2024 | bloomberg.comKyowa Kirin Co. Ltd.July 25, 2024 | wsj.comNQASPA30LMT:IND NASDAQ ASPA Financials Large Mid Cap TR IndexJuly 25, 2024 | seekingalpha.comKyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NCJune 10, 2024 | prnewswire.comKyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024May 8, 2024 | prnewswire.comKYKOY Kyowa Kirin Co., Ltd.April 19, 2024 | seekingalpha.comKyowa Kirin Co Ltd (KY4.SG)April 16, 2024 | finance.yahoo.comKyowa Kirin: First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary SyndromeApril 15, 2024 | finanznachrichten.deFirst Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary SyndromeApril 15, 2024 | finance.yahoo.comKyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On TherapiesApril 12, 2024 | finance.yahoo.comKyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On TherapiesApril 12, 2024 | prnewswire.comKyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024April 2, 2024 | prnewswire.comKYKOF Kyowa Kirin Co., Ltd.March 26, 2024 | seekingalpha.comBreaking Down the $4.3 Million Price Tag Kyowa Kirin’s Gene Therapy for Rare Genetic DiseaseMarch 21, 2024 | msn.comKyowa Kirin's gene therapy most expensive US drug with $4.3 million price tagMarch 20, 2024 | msn.comKyowa Kirin's gene therapy most expensive US drug with $4.3 mln price tagMarch 20, 2024 | reuters.comKyowa buyout Orchard wins FDA nod for rare disease therapyMarch 19, 2024 | msn.comPharma exec talks construction, hiring for new North Carolina plantMarch 18, 2024 | bizjournals.comHow NC city lured Japanese pharma Kyowa Kirin's $200M investmentMarch 8, 2024 | bizjournals.comKyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024March 8, 2024 | finance.yahoo.comHow a North Carolina city lured Japanese pharma's $200M investmentMarch 6, 2024 | bizjournals.com Get Kyowa Kirin News Delivered to You Automatically Sign up to receive the latest news and ratings for KYKOF and its competitors with MarketBeat's FREE daily newsletter. Email Address KYKOF Media Mentions By Week KYKOF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYKOF News Sentiment▼0.000.88▲Average Medical News Sentiment KYKOF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYKOF Articles This Week▼10▲KYKOF Articles Average Week Get Kyowa Kirin News Delivered to You Automatically Sign up to receive the latest news and ratings for KYKOF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AstraZeneca News Today Cosmo Pharmaceuticals News Today JCR Pharmaceuticals News Today Mayne Pharma Group News Today Otsuka News Today Roche News Today Sanofi News Today Scilex News Today Virbac News Today 4Front Ventures News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:KYKOF) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyowa Kirin Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyowa Kirin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
